Courts In Netherlands And UK Differ In Conor/Angiotech Patent Dispute
This article was originally published in The Gray Sheet
Executive Summary
Conor Medsystems and Boston Scientific are both claiming small victories in their ongoing patent dispute related to paclitaxel-eluting stent technology after a Dutch court ruled in favor of Boston Scientific during the same week that a United Kingdom court sided with Conor
You may also be interested in...
Angiotech and Conor settle
Angiotech reaches "favorable" agreement with Johnson & Johnson/Conor Medsystems Sept. 17 to settle all patent litigation ongoing since 2005 related to its paclitaxel-eluting stent technology. Angiotech licenses the patents in question exclusively to Boston Scientific for its Taxus stent. Johnson & Johnson discontinued development of the patent-relevant CoStar paclitaxel-eluting stent and terminated sales of the product overseas in May following disappointing trial results (1"The Gray Sheet" May 14, 2007, p. 9). The settlement covers all ongoing litigation in the UK, the Netherlands and Australia (2"The Gray Sheet" Jan. 22, 2007, p. 12)
Angiotech and Conor settle
Angiotech reaches "favorable" agreement with Johnson & Johnson/Conor Medsystems Sept. 17 to settle all patent litigation ongoing since 2005 related to its paclitaxel-eluting stent technology. Angiotech licenses the patents in question exclusively to Boston Scientific for its Taxus stent. Johnson & Johnson discontinued development of the patent-relevant CoStar paclitaxel-eluting stent and terminated sales of the product overseas in May following disappointing trial results (1"The Gray Sheet" May 14, 2007, p. 9). The settlement covers all ongoing litigation in the UK, the Netherlands and Australia (2"The Gray Sheet" Jan. 22, 2007, p. 12)
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market